Oct 21, 2022 / 01:00PM GMT
Operator
Ladies and gentlemen, good day, and welcome to Q2 FY '23 Earnings Conference Call of Torrent Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Sudhir Menon. Thank you, and over to you, sir.
Sudhir Menon - Torrent Pharmaceuticals Limited - Executive Director of Finance & CFO
Thank you. Good evening, and welcome to Quarter 3 FY '21 Earnings call. Quarter 2 revenue growth was around 7%, which was rated by performance of the branded generic market, which constituted around 70% of the total revenue and registered a Y-o-Y growth of 13%. Growth in the branded generic market was driven by new launch momentum and performance of the top brands. In terms of financial performance, during the quarter, revenues were INR 2,291 crores, up by 7% on a year-on-year basis. Gross margins were 72% and has improved on a sequential basis. There is a one-off income of INR 7 crores in the line-item operating income. And adjusted for that, the operating EBITDA stands at 29.4%. I now hand over to
Q2 2023 Torrent Pharmaceuticals Ltd Earnings Call Transcript
Oct 21, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers